Pacira BioSciences (PCRX) to Release Quarterly Earnings on Wednesday

Pacira BioSciences (NASDAQ:PCRX) will announce its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.72 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Pacira BioSciences Stock Performance

Pacira BioSciences stock traded up $0.77 during mid-day trading on Tuesday, reaching $17.22. The company’s stock had a trading volume of 176,244 shares, compared to its average volume of 862,949. The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.67. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $35.95. The business has a 50 day moving average price of $15.43 and a 200-day moving average price of $21.18. The firm has a market cap of $794.36 million, a price-to-earnings ratio of 12.56 and a beta of 0.82.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, CEO Frank D. Lee purchased 8,264 shares of the business’s stock in a transaction on Monday, August 12th. The stock was bought at an average cost of $12.10 per share, with a total value of $99,994.40. Following the acquisition, the chief executive officer now owns 107,784 shares of the company’s stock, valued at $1,304,186.40. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders purchased 11,176 shares of company stock valued at $136,240. Company insiders own 6.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PCRX. Royal Bank of Canada boosted their price objective on shares of Pacira BioSciences from $14.00 to $15.00 and gave the company a “sector perform” rating in a research report on Friday, October 4th. Raymond James downgraded Pacira BioSciences from an “outperform” rating to a “market perform” rating in a report on Monday, August 12th. Needham & Company LLC dropped their target price on Pacira BioSciences from $43.00 to $22.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. StockNews.com downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. Finally, JPMorgan Chase & Co. restated an “underweight” rating and set a $10.00 price target (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $24.20.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.